Glycated hemoglobin News and Research

RSS

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

The US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted unanimously in support of the use of Signifor (pasireotide) for the treatment of patients with Cushing's disease who require medical therapeutic intervention.

7 Nov 2012

Results from liraglutide and exenatide head-to-head comparison trial on type 2 diabetes

A direct, head-to-head comparison of two of the newer treatments available for type 2 diabetes yielded mixed results.

7 Nov 2012

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.

7 Nov 2012

Primary care improvement program shows benefits of collaboration

A collaborative primary care program aimed at enhancing provision for chronic diseases, patient self-management, access, and Aboriginal healthcare has shown improvement across the vast majority of measures, Australian study findings indicate.

1 Nov 2012

Positive interim data from XBiotech monoclonal antibody Phase II study for type 2 diabetes

XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study using a True Human monoclonal antibody (MABp1) in patients with type 2 diabetes. Results from this study continue to reinforce the role of IL-1α as a master regulator of chronic inflammation in multiple disease states, and the therapeutic benefits of neutralizing antibodies produced from the XBiotech platform.

29 Oct 2012

Results of diabetes management program to be presented at Canadian Cardiovascular Congress

In Canada alone, almost 2 million people are known to be living with diabetes. And around a million more have the disease but are not aware of that fact, and have not been given the tools they need to control their blood sugar and safeguard their health.

29 Oct 2012

HbA1c equally useful across ethnic groups

Currently recommended clinical cutoff points for diabetes diagnosis using glycated hemoglobin should be interpreted similarly in Whites, Blacks, and Hispanics, show findings from a US study.

26 Oct 2012

HbA1c equally useful across ethnic groups

Currently recommended clinical cutoff points for diabetes diagnosis using glycated hemoglobin should be interpreted similarly in Whites, Blacks, and Hispanics, show findings from a US study.

25 Oct 2012

Legume intake reduces heart disease risk in diabetes patients

Diabetes patients who incorporate legumes as part of a low glycemic index diet improve their glycemic control and reduce their risk for coronary heart disease, a study shows.

25 Oct 2012

Canadian Task Force updates diabetes screening guidelines

The Canadian Task Force on Preventive Health Care has updated its recommendations on screening asymptomatic adults for Type 2 diabetes.

19 Oct 2012

Quality of care drops if doctors dictate

Physicians who predominantly dictate patients’ medical notes have worse quality of care than their peers who use structured electronic health record documentation, show study findings.

19 Oct 2012

One rule for one and one for another with diabetes

A joint consensus statement from the European Association for the Study of Diabetes and the American Diabetes Association encourages a shift in attitude over glycemic management in Type 2 diabetes.

12 Oct 2012

HbA1c converter tool launched by NPS

NPS MedicineWise has launched a new online HbA1c converter tool to help people with diabetes understand changes to the way their HbA1c test results are reported in Australia.

10 Oct 2012

Time is of the essence in depressed diabetes patients

Among patients with diabetes and comorbid depression, the time point at which they developed depression may have important implications for their clinical management, say researchers.

5 Oct 2012

Long-term education for patients may futher improve diabetes outcomes

Although there have been significant advances in the provision of diabetes education since 2000, further improvements are still needed, say researchers.

5 Oct 2012

MannKind completes enrollment in AFREZZA Phase 3 clinical studies for type 1 and 2 diabetes

MannKind Corporation today announced that it has completed recruiting patients for two Phase 3 clinical studies of AFREZZA (insulin human [rDNA origin]), an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind's to-be-marketed next-generation inhaler.

5 Oct 2012